What Do These A-Lister Biotech Company IPO’s & Mega A/B Rounds Have in Common?

Image of financial data for article on IPOs

Recent IPO’s from the following list of biotech companies have provided blockbuster capital returns so one might ask, what do these A-list companies have in common?

A provocative & differentiated technology.
Experienced entrepreneurial leadership

Recent examples include:


Mega A/B Rounds

  • EQRx / Alexis Borisey / $700m (A, B)
  • Scorpion / Adam Friedman / $270m (since Q1, 2020)
  • Werewolf / Dan Hicklin / $72m (B)

The third thing in common is their X-Factor:  

They bring in commercial leadership early that execute the Phase specific commercial imperatives and develop defensible commercial valuations – those that stand up to diligence with the board and other industry experts in licensing discussions.  Their Commercial leadership also teach and align the Executive Team and Board on commercialization, (e.g. Market Access, Pricing & Reimbursement, Medical Education, KOL development etc.).

Take a closer look at all these companies – they have the science, the leadership and the Commercial X-factor in place.

Wanna be an A-lister too – contact us.